Leukemia inv16 chromosome abnormality is commonly seen in acute myeloid leukemia, and the exact recurrence rate varies from person to person, with a recurrence rate of 30% to 40% in high-risk patients. Measuring the degree of risk and prognostic assessment of leukemia can be determined by cytogenetics and gene mutation status, etc. Chromosome inv16 abnormalities are common in acute myeloid leukemia. Karyotype inv16 belongs to the low-risk group, and those with chromosome inv16 often have a good prognosis, and those who can be relieved by chemotherapy generally do not need stem cell transplantation. Most patients with low-risk leukemia can achieve complete remission after 1~2 courses of induction remission therapy, but consolidation and maintenance therapy are needed to avoid relapse. Relapse occurs in most patients within 1 year after complete remission. However, the recurrence rate of high-risk patients can reach 30%~40%. Therefore, complete remission should be followed up on time to adhere to consolidation and maintenance therapy. Specific drugs include cytarabine, desmethoxazolam, etc. The use of drugs and treatment should be carried out under the guidance of a physician.